32 results about "Cystine knot" patented technology

The present invention is directed to isolated polypeptides and antibodies suitable for producing therapeutic preparations, methods, and kits relating to bone deposition. One objective of the present invention is to provide compositions that improve bone deposition. Yet another objective of the present invention is to provide methods and compositions to be utilized in diagnosing bone dysregulation. The therapeutic compositions and methods of the present invention are related to the regulation of Wise, Sost, and closely related sequences. In particular, the nucleic acid sequences and polypeptides include Wise and Sost as well as a family of molecules that express a cysteine knot polypeptide.

The invention relates to a strain capable of producing L-arginine and a method for producing the L-arginine by the strain and belongs to the technical field of biological engineering. For the strain, Brevibacterium flavum ATCC 14067 is used as a starting strain; nitrosoguanidine is adopted to carry out mutagenesis step by step; mutant strains with histidine and succinic acid auxotrophic strains are screened out so as to cut off a competitive metabolic pathway; and mutant strains (His-, Suc-, D-Argr, SMCr) with resistances of arginine structural analogs and cysteine structural analogs are screened out. The strain is named as Brevibacterium flavum HX1009, is preserved in the China general microbiological culture collection center, has the preservation number of CGMCC No.4464 and has the genetic characters of histidine auxotroph His-, succinic acid auxotroph Suc-, D-arginine resistance D-Argr and S-methyl cysteine resistance SMCr for improving the yield of the L-arginine. Under the optimized condition, the L-arginine is produced by fermentation on a fermentation tank with the volume of 5L to 5M3 and the arginine production level achieves 50 to 70g/L.

A protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain. Also described herein is an immunoconjugate containing the protein carrier with an antigen conjugated to multiple cysteine residues in the cysteine-rich domain, and an immune composition containing the immunoconjugate and an adjuvant, as well as their uses in eliciting immune responses.

Disclosed are peptides having a cystine knot structural motif and comprising a sequence engineered for specificity against α_IIbβ₃ integrin, found on platelets, and a method of using the same in anti-thrombotic therapies. The present peptides utilize a cystine knot scaffold derived from modified agouti-related protein or agatoxin, An alternate library screening strategy was used to isolate variants of peptides that selectively bound to α_IIbβ₃ integrin or to both α_IIbβ₃ and α_Vβ₃ integrins. Unique consensus sequences were identified within the identified peptides suggesting alternative molecular recognition events that dictate different integrin binding specificities. In addition, the engineered peptides prevented human platelet aggregation in a plasma-based assay and showed high binding affinity for α_IIbβ₃ integrin.

The invention relates to the technical field of chemical sensor, in particular to a phosphorescent chemical sensor for qualitatively detecting homocysteine and an application thereof. Aldehyde group of iridium complex can take cyclization with amido and hydrosulphonyl in the homocysteine to be transformed into hexahydroxy heterocycle and transformed into another compound. The original iridium complex is conjugated with a benzene ring and the aldehyde group and represents as weak red fluorescence while the compound obtained after reaction is not conjugated with the aldehyde group and represents as strong green fluorescence. Ultraviolet and phosphorescent spectrum is used for detecting the result that the complex identifies the homocysteine, thereby showing that the complex has specific response towards the homocysteine, has high sensitivity and can be identified by naked eye, and furthermore, the complex can distinguish cysteine which has a structure very similar as the homocysteine.

The present disclosure provides compositions and methods for reducing or inhibiting vascular inflammation, for example inflammation resulting from unstable blood flow conditions such as oscillatory shear. Representative compositions include an antagonist of BMPs, for example BMP4, or BMP receptors, for example BMPR-I and/or BMPR-II, in an amount sufficient to for inhibiting or reducing vascular inflammation by interfering with binding of bone morphogenic protein or a fragment thereof to bone morphogenic protein receptors. Exemplary BMP antagonists include polypeptides having an eight-, nine-, or ten-membered ring cystine knot structure. Representative BMP antagonists include, but are not limited to the CAN family of proteins, the chordin family that includes chordin and ventroptin, and noggin.

The invention provides a group of peptides as well as a pharmaceutical composition and application thereof. The peptides are as shown in sequence tables; the peptides have amino acid sequences with an analgesic effect, or are pharmacologically acceptable salts of the peptides. A ring is formed by two cysteines at the head end and the tail end of each peptide. A pharmacophore (a structural domain) which has abirritation in the GsMTx-4 peptide is determined by comparing multiple inhibitor cystein knot (ICK)-containing peptide sequences such as GsMTx-4 and GsMTX-2 and carrying out behavior test on a rat pain model.

The present invention provides formulations of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins that are pH stabilized. In particular, the present invention relates to the observation that certain buffers enhance the stability of cysteine knot proteins, including TGF-β superfamily proteins and bone morphogenic proteins. In particular, disclosed herein are liquid and lyophilized formulations prepared with a glycylglycine and tartaric acid buffers to stabilize the pH of the formulation.

Vaccine displaying native antigenic loops of immunoglobulin E is critical for eliciting neutralizing anti-IgE antibodies. The embodiment of the invention enables the display of native antigenic IgE receptor-contacting loops as IgE B-cell vaccines via three steps of constraining methods. The loops of multiple antigenic B-cell epitopes can be molecularly grafted in, and conformationally constrained by the energy favorable flanking beta (b)-stands, i.e., the super b-strands identified in this invention. The constrained loops can be further stabilized in replacing a selective loop within the cystine knot peptide. These dual constrained antigenic loops are then integrated onto thermostable protein scaffolds, folded in the oxidative milieu that provides further conformational constraint and high yield.

The application is directed to TGF analogs/derepressors that bind to and neutralize cystine knot-containing BMP antagonists—such as the CAN subfamily of Cystine-knot proteins including sclerostin. The subject TGF derepressors can be prepared as substantially pyrogen-free pharmaceutical compositions for administration to mammals, in treating diseases such as bone diseases including osteoporosis, and any conditions with lesser-than-desired amount of BMP activity.

The invention relates to a construction method and application of an electrochemical cell sensor for acetamiprid and imidacloprid joint toxicity evaluation, and belongs to the technical field of celldetection. A size-controllable Ag/His-GQD/rGO three-dimensional composite material is prepared, after a glassy carbon electrode is modified with the composite material, L-cysteine is combined to the composite material through sulfydryl, activated folic acid is combined with L-cysteine through amido bonds, cells are fixed, determination is performed through an electrochemical impedance technology,and the electrochemical cell sensor is prepared. Through combination with a three-dimensional composite material, more binding sites can be provided, and the sensitivity of the sensor is improved. Combined with an electrochemical impedance technology, the constructed sensor can determine the Hep G2 cells quickly, and is relatively low in cost. The Hep G2 cell sensor can be used for evaluating thepesticide toxicity, and has a good application prospect in the aspect of pesticide joint toxicity evaluation.

The invention discloses a oral spray preparation and a preparation method thereof. The oral spray preparation is prepared from liquid crystal materials, alginate and mercapto polymer. The preparationmethod of the oral spray preparation comprises the following steps: firstly, dissolving and dispersing a medicine and the liquid crystal materials under an effect of a co-solvent so as to form medicine-carrier liquid crystal nanoparticles; then enveloping the medicine-carrier liquid crystal nanoparticles by adopting the alginate, so that the stability of the medicine-carrier liquid crystal nanoparticles can be greatly improved through the operations, a slow release effect is obvious, and deactivation of the medicine and aggregation and precipitation of the nanoparticles are prevented; the mercapto polymer and half-cystine in a body are combined on an affected part to form a film so as to play isolation and protection effects on the affected part, and therefore, the acting time of the medicine is prolonged, the concentration of the local medicines is obviously increased, development of the medicine is facilitated, the condition that a medicament is diluted due to retention of saliva inan oral cavity so as to lose efficacy is avoided.

The invention relates to the fields of protein chemistry, biology and medicine. More specifically, it relates to the design and preparation of proteinmimics of members of the cystine-knot growth factor superfamily. Further, the invention relates to the use of these proteinmimics as a medicament or prophylactic agent. The invention provides proteinmimics of members of the cystine-knot growth factor superfamily, preferably for use in immunogenic and/or therapeutic compositions.

The invention discloses chickpea four-type 37-amino acids polypeptides, a preparation method thereof and an application thereof in preparing a medicine for treating diabetes or a functional food. Eachpeptide is composed of 37 amino acids, the six cysteines in the molecule and the formed three pairs of disulfide bridges are highly conserved, and the three pairs of disulfide bonds form a cysteine knot domain. The chickpea four-type 37-amino acids polypeptides can be dissolved in polar solvents such as water, which are stable to heat and resistant to hydrolysis of protease in human digestive tract. The preparation cost is lower than that of insulin and other peptide drugs; the product is not only can be used for treating symptomatic doeases, but also treats the root, and can be used for recovering the quality and function of diseased pancreas at varying degrees; the product reduces or eliminates the body's insulin resistance, can be developed to oral dosage form, and is easier to use than insulin and other peptide drugs; while in use, no risk of hypoglycemia is generated; and the product is derived from edible plant chickpeas and has no toxic side effects.

The invention discloses an anticoagulant drug based on cobra venom PIII type metalloprotease. The cobra venom PIII type metalloprotease is extracted from snake venom of naja atra and then purified. The metalloprotease is single chain glycoprotein. The structure analysis shows that metalloprotease has three structural domains: metalloprotease structural domain, disintegrin like structural domain, and cysteine enriched structural domain, and belongs to PIII type cobra venom metalloprotease. The metalloprotease is named as Atrase A and Atrase B; and the sequences of Atrase A and Atrase B are represented by SEQ ID No.1 and SEQ ID No.2 respectively. Target protein and anticoagulant drugs thereof have multiple anticoagulant effects: preventing multiple blood coagulation factors; reducing fibrinogen level; preventing platelet aggregation; and preventing complement so as to relieve abnormal blood coagulation caused by inflammation.